<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053220</url>
  </required_header>
  <id_info>
    <org_study_id>ColoAd1-1002</org_study_id>
    <nct_id>NCT02053220</nct_id>
  </id_info>
  <brief_title>Mechanism of Action Trial of ColoAd1</brief_title>
  <acronym>MOA</acronym>
  <official_title>A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PsiOxus Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PsiOxus Therapeutics Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour&#xD;
      tissue when administered by intra-tumoural injection or within colon, non-small cell lung,&#xD;
      bladder and renal cell tumour tissues following ColoAd1 administration by intravenous&#xD;
      infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite measure of viral delivery and spread</measure>
    <time_frame>Up to Day 25</time_frame>
    <description>To assess the pattern of viral delivery and viral spread of ColoAd1 within tumour tissue when administered either by intra-tumoural injection or by intravenous infusion. Viral delivery and spread will be measured by immunohistochemical staining for ColoAd1 in tumour sections taken from patients. Presence of virus will also be detected by qPCR analysis of tumour tissue.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Resectable Colon Cancer</condition>
  <condition>Resectable Non-small Cell Lung Cancer</condition>
  <condition>Resectable Bladder Cancer</condition>
  <condition>Resectable Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Intra-tumoural cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-venous cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Colo-Ad1</intervention_name>
    <description>Oncolytic virus</description>
    <arm_group_label>Intra-tumoural cohort</arm_group_label>
    <arm_group_label>Intra-venous cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients must meet all the following criteria to be eligible for participation:&#xD;
&#xD;
          -  Able and willing to provide written informed consent and to comply with the study&#xD;
             protocol&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patients with histologically confirmed resectable colon cancer, NSCLC (squamous and&#xD;
             non-squamous), bladder cancer (urothelial cell carcinoma) or RCC (renal cell&#xD;
             carcinoma), scheduled for resection of primary tumour and with planned resection of&#xD;
             draining lymph nodes for colon cancer&#xD;
&#xD;
          -  Diagnostic colonoscopy performed at the study centre (Cohorts A and B only) or a&#xD;
             referral centre (Cohort B only) and a report from this colonoscopy available for the&#xD;
             study&#xD;
&#xD;
          -  Tumour size of 3 cm or more in diameter as estimated during diagnostic colonoscopy for&#xD;
             cohorts A and B or by CT-scan for cohorts C, D and E.&#xD;
&#xD;
          -  At least 2 weeks since the last dose of any intravenous systemic chemotherapy at time&#xD;
             of first administration of ColoAd1&#xD;
&#xD;
          -  Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for&#xD;
             their malignancies.&#xD;
&#xD;
          -  Able to undergo surgery with general anaesthesia&#xD;
&#xD;
          -  Surgery planned and administration of ColoAd1 feasible within&#xD;
&#xD;
               -  15 days of planned surgery (following IT administration or following first dose&#xD;
                  of IV administration) for cohorts A and B&#xD;
&#xD;
               -  10 - 25 days of first ColoAd1 administration for cohorts C, D and E&#xD;
&#xD;
          -  ECOG Performance Status Score of 0 or 1&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance using the&#xD;
                  Cockcroft-Gault formula ≥ 60 mL/min, or measured creatinine clearance ≥60 mL/min,&#xD;
&#xD;
               -  Absence of clinically significant haematuria on urinalysis: dipstick &lt; 2+&#xD;
&#xD;
               -  Absence of clinically significant proteinuria on urinalysis: dipstick &lt; 2+.&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
               -  serum bilirubin &lt;1.5 x ULN&#xD;
&#xD;
               -  AST and ALT ≤ 3 x ULN&#xD;
&#xD;
          -  Adequate bone marrow function:&#xD;
&#xD;
               -  ANC ≥ 1.5 x 109/L,&#xD;
&#xD;
               -  platelets ≥ 100 x 109/L,&#xD;
&#xD;
               -  haemoglobin ≥ 90 g/L&#xD;
&#xD;
          -  Adequate coagulation tests: INR ≤ 1.5 x ULN;&#xD;
&#xD;
          -  For females of childbearing potential (defined as &lt;2 years after last menstruation or&#xD;
             not surgically sterile), a negative pregnancy test must be documented prior to&#xD;
             enrolment;&#xD;
&#xD;
          -  For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile&#xD;
             (absence of ovaries and/or uterus): agreement to use two adequate methods of&#xD;
             contraception, including at least one method with a failure rate of &lt; 1% per year&#xD;
             (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during&#xD;
             the treatment period and for at least 3 months after the last dose of study drug;&#xD;
&#xD;
          -  For men: agreement to use a barrier method of contraception during the treatment&#xD;
             period and for at least 6 months after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria for all patients:&#xD;
&#xD;
        Patients who meet any of the following criteria are not eligible for enrolment:&#xD;
&#xD;
          -  Rectal tumours; (cohorts A and B);&#xD;
&#xD;
          -  An obstructive tumour of the intestine (cohorts A and B only) or of the urinary tract&#xD;
             (cohort D);&#xD;
&#xD;
          -  Any condition necessitating surgery in less than 8 days (cohorts A or B) or 10 days&#xD;
             (cohorts C, D or E);&#xD;
&#xD;
          -  Pregnant or lactating (nursing) women;&#xD;
&#xD;
          -  Known and/or a history or evidence of significant immunodeficiency due to underlying&#xD;
             illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids at doses&#xD;
             higher than dexamethasone 10 mg or equivalent, or other immunosuppressive medications&#xD;
             including cyclosporine, azathioprine, interferons, within the past 4 weeks);&#xD;
&#xD;
          -  Splenectomy&#xD;
&#xD;
          -  Prior allogeneic or autologous bone marrow or organ transplantation&#xD;
&#xD;
          -  Active infections requiring antibiotics, physician monitoring, or recurrent fevers&#xD;
             &gt;38.0 degrees centigrade associated with a clinical diagnosis of active infection&#xD;
&#xD;
          -  Active viral disease, positive serology for HIV, hepatitis B or hepatitis C&#xD;
&#xD;
          -  Use of the following anti-viral agents:&#xD;
&#xD;
               -  ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1;&#xD;
&#xD;
               -  or PEG-IFN (within 14 days prior to day 1);&#xD;
&#xD;
          -  Administration of an investigational drug within 28 days prior to first dose of&#xD;
             ColoAd1&#xD;
&#xD;
          -  Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of&#xD;
             ColoAd1&#xD;
&#xD;
          -  Another primary malignancy within the past 3 years (except for non-melanoma skin&#xD;
             cancer or cervical cancer in situ)&#xD;
&#xD;
          -  Known CNS metastasis&#xD;
&#xD;
          -  Inflammatory diseases of the bowel (cohorts A and B only) or any inflammatory disease&#xD;
             that may require treatment with corticosteroids.&#xD;
&#xD;
          -  Any condition or illness that, in the opinion of the Investigator or the medical&#xD;
             monitor, would compromise patient safety or interfere with the evaluation of the&#xD;
             safety of the drug&#xD;
&#xD;
          -  Known allergy to treatment medication or its excipients&#xD;
&#xD;
          -  Any other medical or psychological condition that would preclude participation in the&#xD;
             study or compromise ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro CIOCC</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0277-7</url>
    <description>Journal link for MOA study publication</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

